Economic evaluation of HIV prevention programs

Annual Review of Public Health

Volumn 17, Issue , 1996, Pages 467-488

  Holtgrave, David R ^a   Qualls, Noreen L ^b   Graham, John D ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c HARVARD CENTER FOR RISK ANALYSIS   (United States)

Author keywords

AIDS; cost; evaluation; HIV; prevention

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PRIORITY JOURNAL; REVIEW;

EID: 0029918824     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pu.17.050196.002343     Document Type: Review

References (114)

1. Allen UD, Read S, Gafni A. 1992. Zidovudine for chemoprophylaxis after occupational exposure to HIV-infected blood: an economic evaluation. Clin. Infect. Dis. 14:822-30
2. Altman R, Shahied SI, Pizzuti W, Brandon DN, Anderson L, Freund C. 1992. Premarital HIV-1 testing in New Jersey. J. Acquired Immune Defic. Syndr. 5:7-11
3. Arno PS, Green J, Mofenson L, Bonuck K, Futterman D, Shenson D. 1991. Early intervention in pediatric HIV disease: the economic impact. Int. Conf. AIDS 7:72 (Abstr. No. TU.D.62)
4. Bloom DE, Glied S. 1991. Benefits and costs of HIV testing. Science 252:1798-804
5. Brandeau ML, Owens DK, Sox CH, Wachter RM. 1993. Screening women of childbearing age for human immunodeficiency virus: a model-based policy analysis. Manage. Sci. 39:72-92
6. Buxton MJ, Dubois DJ, Turner RR, Sculpher MJ, Robinson PA, Searcy C. 1991. Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. Comparison of fluconazole and amphotericin B-based therapies. J. Infect. 23:17-31
7. Caceres CF, Rosasco AM, Mandel JS, Hearst N. 1994. Evaluating a school-based intervention for STD/AIDS prevention in Peru. J Adolesc. Health 15: 582-91
8. Cameron C, Shepard J, Mann J, Somaini B, Dubois JA, et al. 1990. Prevention scenarios: Swiss AIDS programme. Int. Conf. AIDS 6:290 (Abstr. No. F.D.834)
9. Castellano AR, Nettleman MD. 1991. Cost and benefit of secondary prophylaxis for pneumocystis carinii pneumonia. JAMA 266:820-24
10. Cent. Dis. Control Prev. 1995. Update: acquired immunodeficiency syndrome - United Stales, 1994. Morbid. Mortal. Wkly. Rep. 44:64-67
11. Chavey WE, Cantor SB, Clover RD, Reinarz JA, Spann SJ. 1994. Cost-effectiveness analysis of screening health care workers for HIV. J. Fam. Pract. 38:249-57
12. Cheung TW, Fahs M, Sacks HS. 1990. Cost-effectiveness analysis of early treatment of HIV disease with zidovudine (AZT). Int. Conf. AIDS 6:473 (Abstr. No. 4078)
13. Choi KH, Coates TJ. 1994. Prevention of HIV infection. AIDS 8:1371-89
14. Clark HW, Corbett JM. 1993. Needle exchange programs and social policy. J. Ment. Health Admin. 20:66-71
15. Cleary PD, Barry MJ, Mayer KH, Brandt AM, Goslin L, Fineberg HV. 1987. Compulsory premarital screening for the human immunodeficiency virus: technical and public health considerations. JAMA 258:1757-62
16. Cole G, Gorsky R, MacGowan R, Collier C. 1993. Costs and cost-effectiveness of HIV prevention activities in methadone treatment clinics. Int. Conf. AIDS 9:749 (Abstr. No. PO-C24-3191)
17. Cowley P. 1993. Preliminary cost-effectiveness analysis of an AIDS vaccine in Abidjan, Ivory Coast. Health Policy 24: 145-53
18. Cowper P, Oddone EZ, Matchar D, Hamilton J, Hartigan P, et al. 1992. Factors influencing the cost-effectiveness of early versus later zidovudine (AZT) treatment of symptomatic human immunodeficiency virus infection. Med. Decis. Making 12:340 (Abstr.)
19. Crystal S, Dengelegi L, Beck P, Dejowski E. 1990. AIDS contact notification: initial program results in New Jersey. AIDS Educ. Prev. 2:284-95
20. DeCiantis ML, DeBuono B, Scott HD, Carpenter C. 1990. Routine HIV testing in an acute care hospital inpatient setting. Int. Conf AIDS 6:332 (Abstr. No. Th.D.826)
21. de Moya EA, Peguera CP, Charles W, Adams KG, Gomes MF, et al. 1992. Measuring the costs and benefits of HIV screening systems in Trinidad and Tobago, the Dominican Republic and the Philippines. Int. Conf. AIDS 8:D454 (Abstr. No. PoD5402)
22. Div. HIV/AIDS Prev. 1994. HIV/AIDS Surveillance Report: US HIV and AIDS Cases Reported through December 1994 (Year-end ed.) 6:7,19. CDC, Natl. Cent. Prev. Serv., Atlanta
23. Drummond M, Davies L. 1990. Economic evaluation of programmes for AIDS and HIV infection: methodological issues. In Economic Aspects of AIDS and HIV Infection, ed. D Schwefel, R Leidl, J Rovira, MF Drummond, pp. 107-17. Berlin: Springer-Verlag
24. Drummond MF, Stoddart GL, Torrance GW. 1987. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford Univ. Press
25. Eisenstaedt RS, Getzen TE. 1988. Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis. Am. J. Public Health 78:450-54
26. Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, et al. 1995. The cost effectiveness of preoperative autologous blood donations. N. Engl. J. Med. 332: 719-24
27. Forsythe S, Schvartz E, Janowitz B, Suarez E, de Moya T, et al. 1992. Measuring costs and benefits of target condom distribution programs in Latin American and Caribbean countries. Int. Conf. AIDS 8:D454 (Abstr. No. PoD5403)
28. Freedberg KA, Cohen CJ, Barber TW. 1992. Preventing mycobacterium avium complex infection in patients with AIDS: a cost-effectiveness analysis. Med. Decis. Making 12:339 (Abstr.)
29. Freedberg KA, Tosteson ANA, Cohen CJ, Cotton DJ. 1991. Primary prophylaxis for pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis. J. Acquired Immune Defic. Syndr. 4:521-31
30. Freedberg KA, Tosteson ANA, Cotton DJ, Goldman L. 1992. Optimal management strategies for HIV-infected patients who present with cough or dyspnea: a cost-effectiveness analysis. J. Gen. Intern. Med. 7:261-72
31. Fulop G, Strain J, Fahs M, Sacks H. 1989. Scatter bed versus cluster unit treatment of AIDS inpatients. Int. Conf. AIDS 5:1045 (Abstr. No. T.H.P.7)
32. Gail MH, Preston D, Piantadosi S. 1989. Disease prevention models of voluntary confidential screening for human immunodeficiency virus (HIV). Stat. Med. 8:59-81
33. Gelles GM. 1993. Costs and benefits of HIV-1 antibody testing of donated blood. J. Policy Anal. Manage. 12:512-31
34. Giesecke J, Ramstedt K, Granath F, Ripa T, Rado G, Westrell M. 1991. Efficacy of partner notification for HIV infection. Lancet 338:1096-100
35. Gorsky RD, MacGowan RJ, Swanson NM, DelGado BP. 1995. Prevention of HIV infection in drug abusers: a cost analysis. Prev. Med. 24:3-8
36. Guinan ME, Farnham PG, Holtgrave DR. 1994. Estimating the value of preventing a human immunodeficiency virus infection. Am. J. Prev. Med. 10:1-4
37. Harris RL, Boisaubin EV, Salyer PD, Semands DF. 1990. Evaluation of a hospital admission HIV antibody voluntary screening program. Infect. Control Hosp. Epidemiol. 11:628-34
38. Healy JC, Frankfurter SA, Graves BK. 1992. Autologous predeposit in total hip arthroplasty: a cost-effectiveness analysis. Med. Decis. Making 12:339 (Abstr.)
39. Hellinger FJ. 1992. Forecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry 29:356-65
40. Hellinger FJ. 1993. The lifetime cost of treating a person with HIV. JAMA 270: 474-78
41. Holtgrave DR. 1994. Cost analysis and HIV prevention interventions. Am. Psychol. 49:1088-89
42. Holtgrave DR, Qualls NL. 1994. HIV prevention programs. Science 266:16
43. Holtgrave DR, Qualls NL. 1995. Threshold analysis and HIV prevention programs. Med. Decis. Making. In press
44. Holtgrave DR, Qualls NL, Curran JW, Valdiserri RO, Guinan ME, Parra WC. 1995. An overview of the effectiveness and efficiency of HIV prevention programs. Public Health Rep. 110:134-46
45. Holtgrave DR, Valdiserri RO, Gerber AR, Hinman AR. 1993. Human immunodeficiency virus counseling, testing, referral, and partner notification services: a cost-benefit analysis. Arch. Intern. Med. 153:1225-30
46. Holtgrave DR, Valdiserri RO, West GA. 1994. Quantitative economic evaluations of HIV-related prevention and treatment services: a review. Risk 5:29-47
47. Houshyar A. 1991. Screening pregnant women for HIV antibody: cost-benefit analysis. AIDS Public Policy J. 6:98-103
48. Janssen RS, Gorsky R, Raimondi V. 1994. Costs of strategies for routine HIV counseling and testing of U.S. hospital patients. Int. Conf. AIDS 10:300 (Abstr. No. PC0586)
49. Johanson JF, Sonnenberg A. 1990. Efficient management of diarrhea in the acquired immunodeficiency syndrome (AIDS): a medical decision analysis. Ann. Intern. Med. 112:942-48
50. Judson FN. 1990. Partner notification for HIV control. Hosp. Pract. 25:63-73
51. Kahn JG. 1993. Are NEPs cost-effective in preventing HIV infection? In The Public Health Impact of Needle Exchange Programs in the United States and Abroad, ed. P Lurie, AL Reingold, 18:473-509. Univ. Calif., Sch. Public Health, Berkeley/Univ. Calif., Inst. Health Policy Stud., San Francisco
52. Kahn JG. 1993. How much does it cost to operate NEPs? See Ref. 51, pp. 243-59
53. Kahn JG, Washington AE. 1994. Optimizing the policy impact of HIV modeling. In Modeling the AIDS Epidemic: Planning, Policy, and Prediction, ed. EH Kaplan, ML Brandeau, 12:217-35. New York: Raven
54. Kahn JG, Washington AE, Showstack JA, Berlin M, Phillips K. 1992. Bleach distribution. In Updated Estimates of the Impact and Cost of HIV Prevention in Injection Drug Users, 7:95-103. Univ. Calif., Inst. Health Policy Stud., San Francisco
55. Kahn JG, Washington AE, Showstack JA, Berlin M, Phillips K. 1992. Counseling and testing. See Ref. 54, pp. 47-66
56. Kahn JG, Washington AE, Showstack JA, Berlin M, Phillips K. 1992. Extended counseling/education. See Ref. 54, pp. 67-77
57. Kahn JG, Washington AE, Showstack JA, Berlin M, Phillips K. 1992. Partner notification. See Ref. 54, pp. 78-94
58. Kahn JG, Washington AE, Showstack JA, Berlin M, Phillips K. 1992. Treatment of drug dependency. See Ref. 54, pp. 104-22
59. Kelly JA, Murphy DA, Sikkema KJ, Kalichman SC. 1993. Psychological interventions to prevent HIV infection are urgently needed: new priorities for behavioral research in the second decade of AIDS. Am. Psychol. 48:1023-34
60. Kongsin S, Dhiratayakinant K. 1994. Cost benefit analysis of screening HIV antibody (AIDS) in venereal disease patients. Int. Conf. AIDS 10:385 (Abstr. No. PD0720)
61. Lampinen TM. 1991. Cost-effectiveness of drug abuse treatment for primary prevention of acquired immunodeficiency syndrome: epidemiologic considerations. In Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug Treatment, Res. Monogr. 113, ed. WS Cartwright, JM Kaple, pp. 114-28. Rockville, MD: Natl. Inst. Drug Abuse
62. Laufer FN, Chiarello LA. 1994. Application of cost-effectiveness methodology to the consideration of needle-stick-prevention technology. Am. J. Infect. Control 22:75-82
63. Laupacis A, Feeny D, Detsky AS, Tugwell PX. 1992. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can. Med. Assoc. J. 146:473-81
64. Laupacis A, Feeny D, Detsky AS, Tugwell PX. 1993. Tentative guidelines for using clinical and economic evaluations revisited. Can. Med. Assoc. J. 148:927-29
65. Lawrence VA, Gafni A, Kroenke K. 1993. Preoperative HIV testing: Is it less expensive than universal precautions? J. Clin. Epidemiol. 46:1219-27
66. Le Gales C, Moatti JP, Paris-Tours Study Group of Antenatal Transmission of HIV, Group '9 Maternités.' 1990. Cost-effectiveness of HIV screening of pregnant women in hospitals of the Paris area. Eur. J. Obstet. Gynecol. Reprod. Biol. 37:25-33
67. Le Gales C, Seror V, Courpotin C, Tricoire J, Reynert P, Diakale F. 1992. Cost-benefit analysis of HIV prenatal screening in France. Int. Conf. AIDS 8:C380 (Abstr. No. PoC4824)
68. Levine AA, Sandler RS. 1994. Screening for human immunodeficiency virus in physicians: Who should we test and what will it cost? NC Med J. 55:136-40
69. Luce BR, Simpson K. 1995. Methods of cost-effectiveness analysis: areas of consensus and debate. Clin. Ther 17: 109-25
70. Lurie P, Avins AL, Phillips KA, Kahn JG, Lowe RA, Ciccarone D. 1994. The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA 272:1832-38
71. Mathews WC, Fenton C, Fullerton S, Abramson I, Coley E, La Belle J. 1990. Cost-effectiveness of secondary PCP prophylaxis using aerosolized pentamidine: evaluation of a hospital-based program. Int. Conf AIDS 6:376 (Abstr. No. 2088)
72. McCarthy BD, Schreiber MB, Ward RE, Saravolatz LD. 1994. Should all pregnant women be screened for HIV infection? Med. Decis. Making 14:437 (Abstr.)
73. McCarthy BD, Wong JB, Munoz A, Sonnenberg FA. 1993. Who should be screened for HIV infection? A cost-effectiveness analysis. Arch. Intern. Med. 153:1107-16
74. McFarland W, Kahn JG, Katzenstein D, Mvere D, Shamu R. 1994. Blood donor deferral by HIV risk factors is cost-effective in Zimbabwe. Int. Conf. AIDS 10:8 (Abstr. No. 326C)
75. McKay NL, Phillips KM. 1991. An economic evaluation of mandatory premarital testing for HIV. Inquiry 28:236-48
76. Mendelson DN, Sandler SG. 1990. A model for estimating incremental benefits and costs of testing donated blood for human immunodeficiency virus antigen (HIV-Ag). Transfusion 30:73-75
77. Moses S, Plummer FA, Ngugi EN, Nagelkerke NJD, Anzala AO, Ndinya-Achola JO. 1991. Controlling HIV in Africa: effectiveness and cost of an intervention in a high-frequency STD transmitter core group. AIDS 5:407-11
78. Mullins JR, Harrison PB. 1993. The questionable utility of mandatory screening for the human immunodeficiency virus. Am. J. Surg. 166:676-79
79. Nahmias S, Feinstein CD. 1990. Screening strategies to inhibit the spread of AIDS. Socio-Econ. Plan. Sci. 24:249-60
80. Owens DK, Harris RA, Scott PM, Nease RF Jr. 1995. Screening surgeons for HIV infection: a cost-effectiveness analysis. Ann. Intern. Med. 122:641-52
81. Owens DK, Nease RF, Harris R. 1993. Use of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings. Med. Decis. Making 13:395 (Abstr.)
82. Owens DK, Nease RF, Harris RA. 1993. Screening for HIV infection in acute-care settings: determinants of cost-effectiveness. Med. Decis. Making 13:395 (Abstr.)
83. Paltiel AD, Kaplan EH. 1991. Modeling zidovudine therapy: a cost-effectiveness analysis. J. Acquired Immune Defic. Syndr. 4:795-804
84. Paltiel AD, Kaplan EH. 1994. Cost-effectiveness of voluntary HIV testing in acute-care hospitals. Med. Decis. Making 14:439 (Abstr.)
85. Patrick DL, Erickson P. 1993. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation New York: Oxford Univ. Press
86. Pavia AT, Benyo M, Niler L, Risk I. 1993. Partner notification for control of HIV: results after 2 years of a statewide program in Utah. Am. J. Public Health 83:1418-24
87. Petersen LR, White CR, Premarital Screening Study Group. 1990. Premarital screening for antibodies to human immunodeficiency virus type 1 in the United States. Am. J. Public Health 80:1087-90
88. Phillips KA, Lowe RA, Kahn JG, Lurie P, Avins AL, Ciccarone D. 1994. The cost-effectiveness of HIV testing of physicians and dentists in the United States. JAMA 271:851-58
89. Posen AS, Turvey J, Goldstone I. 1992. Economic implications of Vancouver's needle exchange. Int. Conf. AIDS 8:D454 (Abstr. No. PoD5406)
90. Prev. Effectiveness Activity. 1994. A Practical Guide to Prevention Effectiveness: Decision and Economic Analyses. CDC, Epidemiol. Program Off., Atlanta
91. Ramsey SD, Nettleman MD. 1992. Cost-effectiveness of prophylactic AZT following needlestick injury in health care workers. Med. Decis. Making 12: 142-48
92. Revicki D, Simpson KN, LaVallee R, Palmer C. 1993. Cost-utility of adding ddC to AZT treatment for AIDS patients in the United States. Int. Conf. AIDS 9:920 (Abstr. No. PO-D28-4216)
93. Rose DN, Schechter CB, Sacks HS. 1993. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. Am. J. Med. 94:160-68
94. Russo G, La Croix SJ. 1992. A second look at the cost of mandatory human immunodeficiency virus and hepatitis B virus testing for healthcare workers performing invasive procedures. Infect. Control Hosp. Epidemiol. 13:107-10
95. Rutherford GW, Woo JM, Neal DP, Rauch KJ, Geoghegan C, et al. 1991. Partner notification and the control of human immunodeficiency virus infection: two years of experience in San Francisco. Sex. Transm. Dis. 18:107-10
96. Schopper D, Auvert B. 1994. Estimating the global impact of interventions to decrease the spread of HIV in developing countries by the year 2000. Int. Conf. AIDS 10:330 (Abstr. No. PC0253)
97. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. 1991. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 114:798-802
98. Sell RL, Jovell AJ, Siegel JE. 1994. HIV screening of surgeons and dentists - a cost-effectiveness analysis. Infect. Control Hosp. Epidemiol. 15(10):635-45
99. Smith MD, Murray RB, McAvinue S, Suldan M, Chaisson RE. 1990. Cost-effectiveness of aerosolized pentamidine (AP) prophylaxis against pneumocystis carinii pneumonia. Int. Conf. AIDS 6:289 (Abstr. No. F.D.830)
100. Spencer NE, Hoffman RE, Raevsky CA, Wolf FC, Vernon TM. 1993. Partner notification for human immunodeficiency virus infection in Colorado: results across index case groups and costs. Int. J. STD AIDS 4:26-32
101. Stock SR, Gafni A, Bloch RF. 1990. Universal precautions to prevent HIV transmission to health care workers: an economic analysis. Can. Med. Assoc. J. 142:937-46
102. Sweat M, Siegel G, de Zoysa I, Coates T. 1994. Identifying goals for behavior change programs in urban African settings: high effectiveness and moderate coverage maximize impact and cost-effectiveness. Int. Conf. AIDS 10:300 (Abstr. No. PC0589)
103. Tengs TO, Adams M, Pliskin JS, Safran DG, Siegel JE, et al. 1994. Five-Hundred Life-Saving Interventions and their Cost-Effectiveness. Boston: Harvard Sch. Public Health, Cent. Risk Anal.
104. Tramarin A, Milocchi F, Tolley K, Vaglia A, Marcolini F, et al. 1992. An economic evaluation of home-care assistance for AIDS patients: a pilot study in a town in northern Italy. AIDS 6: 1377-83
105. Turnock BJ, Kelly CJ. 1989. Mandatory premarital testing for human immunodeficiency virus: the Illinois experience. JAMA 261:3415-18
106. Wachter RM, Luce JM, Safrin S, Berrios DC, Charlebois E, Scitovsky AA. 1995. Cost and outcome of intensive care for patients with AIDS, pneumocystis carinii pneumonia, and severe respiratory failure. JAMA 273:230-35
107. Watson-Williams EI, Kataaha P, Senyonga P, Kyeyune D. 1994. Cost-effectiveness of Uganda blood programme. Int. Conf. AIDS 10:8 (Abstr. No. 325C)
108. Weinstein MC, Graham JD, Siegel JE, Fineberg HV. 1989. Cost-effectiveness analysis of AIDS prevention programs: concepts, complications, and illustrations. In AIDS: Sexual Behavior and Intravenous Drug Use, ed. CF Turner, HG Miller, LE Moses, pp. 471-99. Washington, DC: Natl. Acad. Sci.
109. Wiebel W, Jimenez A, Johnson W, Ouellet L, Murray J, O'Brien M. 1993. Positive effect on HIV seroconversion of street outreach intervention with IDU in Chicago, 1988-1992. Int. Conf. AIDS 1:96 (Abstr. No. WS-C15-2)
110. Wilfert CM. 1994. Mandatory screening of pregnant women for the human immunodeficiency virus. Clin. Infect. Dis. 19:664-66
111. Wright-De Aguero LK, Gorsky RD, Seeman GM. 1995. Cost of outreach for HIV prevention among drug users and youth at risk. Drugs Soc. In press
112. Wykoff RF, Heath CW, Hollis SL, Leonard ST, Quiller CB, et al. 1988. Contact tracing to identify human immunodeficiency virus infection in a rural community. JAMA 259:3563-66
113. Yawn BP. 1992. Clinical decision analysis of HIV screening. Fam. Med. 24: 355-61
114. Zowall H, Fraser RD, Gilmore N, Deutsch A, Graver S. 1990. HIV antibody screening among immigrants: a cost-benefit analysis. Can. Med. Assoc. J. 143:101-7